Pramlintide
Also known as: Symlin, Amylin Analog
Pramlintide is a synthetic analog of human amylin that regulates postprandial glucose by slowing gastric emptying and suppressing glucagon secretion. This peptide hormone mimics natural amylin function to improve glycemic control in diabetes research.
Pramlintide is a 3,949 Da research peptide. Pramlintide is a synthetic analog of human amylin that regulates postprandial glucose by slowing gastric emptying and suppressing glucagon secretion. This peptide hormone mimics natural amylin function to improve glycemic control in diabetes research.
Also called: Symlin, Amylin Analog
3,949
Molecular Weight
Daltons
3
Strong Evidence
benefits
4
Studies Cited
peer-reviewed
15-60
Typical Dose
mcg
Overview
Pramlintide represents a synthetic version of human amylin, a hormone co-secreted with insulin from pancreatic beta cells. The peptide contains 37 amino acids and functions as an amylin receptor agonist, providing multiple mechanisms for glucose regulation. Unlike native amylin which aggregates easily, pramlintide maintains stability through strategic amino acid substitutions. Research applications focus on postprandial glucose control, gastric emptying modulation, and appetite regulation. The compound demonstrates particular utility in studying amylin physiology and developing diabetes treatment protocols. Clinical studies have established its role as an adjunctive therapy for insulin-using diabetics.
Key Takeaways: Pramlintide
- Strongest evidence supports Pramlintide for postprandial glucose control and weight loss support
- Research doses typically range from 15 to 60 mcg via subcutaneous
- 3 benefits with strong evidence, 3 moderate, 0 preliminary
- Half-life: 48 minutes
- 4 cited research studies in this guide
Mechanism of Action
Pramlintide activates amylin receptors (AMY1, AMY2, AMY3) located in the area postrema and other brain regions. Receptor binding triggers several glucose-lowering mechanisms: slowed gastric emptying reduces nutrient absorption rate, suppressed postprandial glucagon secretion prevents hepatic glucose output, and enhanced satiety signals decrease food intake. The peptide also modulates gastric acid secretion and promotes beta-cell preservation through reduced glucotoxicity. These combined effects result in improved postprandial glucose excursions without increasing hypoglycemia risk when used appropriately.
Research Benefits
Pramlintide at a Glance
Pramlintide activates amylin receptors (AMY1, AMY2, AMY3) located in the area postrema and other brain regions.
Postprandial Glucose Control
Strong EvidenceReduces post-meal glucose spikes by 30-50% through delayed gastric emptying and suppressed glucagon release, demonstrated consistently across multiple clinical trials
Weight Loss Support
Strong EvidencePromotes 2-4 kg weight reduction over 6 months through enhanced satiety and reduced caloric intake, with effects maintained during long-term use
Improved HbA1c Levels
Strong EvidenceAchieves 0.4-0.7% reduction in HbA1c when added to insulin therapy, representing clinically meaningful glycemic improvement
Reduced Insulin Requirements
Moderate EvidenceAllows 15-25% reduction in mealtime insulin doses while maintaining glycemic targets, decreasing overall insulin exposure
Gastric Emptying Modulation
Moderate EvidenceSlows gastric emptying rate by 40-60% in controlled studies, providing therapeutic benefit for gastroparesis research
Glucagon Suppression
Moderate EvidenceReduces inappropriate postprandial glucagon secretion by 50-70%, addressing a key pathophysiologic defect in diabetes
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Type 1 diabetes research | 15–60 mcg | subcutaneous |
| Type 2 diabetes research | 60–120 mcg | subcutaneous |
| Gastric emptying studies | 30–90 mcg | subcutaneous |
Frequency
Before major meals (3 times daily)
Timing
Immediately before eating
Cycle Length
Continuous use in research protocols
Research Notes
- 1Start with lowest dose and titrate based on tolerability
- 2Skip dose if meal is skipped or contains <30g carbohydrates
- 3Administer at different injection site than insulin
- 4Monitor for nausea during dose escalation phase
Reconstitution Guide
Standard Reconstitution
Vial Size
5 mg
Bacteriostatic Water
5 mL
Concentration
10 mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
Pramlintide vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 5 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at 2-8°C. 28 days after opening.
Storage Temperature
2-8°C
Shelf Life
28 days after opening
Important Notes
- •Available as pre-filled pen injectors (0.6mg/ml concentration)
- •Do not shake or freeze the solution
- •Discard if solution appears cloudy or contains particles
- •Store unopened vials in refrigerator until expiration date
Pramlintide Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
Pramlintide Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Nausea (28-48% incidence)
- !Vomiting (7-15% incidence)
- !Anorexia and decreased appetite
- !Abdominal pain and cramping
- !Injection site reactions
- !Headache (5-10% incidence)
- !Dizziness and fatigue
- !Severe hypoglycemia risk when combined with insulin
- !Diarrhea (less common)
- !Allergic reactions (rare but serious)
Potential Interactions
- ⚡Insulin - increased hypoglycemia risk, requires dose adjustment
- ⚡Alpha-glucosidase inhibitors - may have additive gastric effects
- ⚡Oral medications - delayed absorption due to slowed gastric emptying
- ⚡Anticholinergic drugs - may counteract gastric motility effects
- ⚡Alcohol - enhanced hypoglycemia risk when combined with insulin
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes
Six-month study showing 0.6% HbA1c reduction and 1.6 kg weight loss in type 2 diabetics receiving pramlintide with insulin
Effect of pramlintide on gastric emptying in subjects with type 1 diabetes mellitus
Demonstrated 50% reduction in gastric emptying rate with pramlintide administration in type 1 diabetic subjects
Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in patients with type 1 diabetes
Multi-center trial showing significant postprandial glucose reduction without increased hypoglycemia in type 1 diabetics
Long-term effects of pramlintide on diabetic complications and mortality
Two-year follow-up study demonstrating sustained glycemic benefits and weight loss maintenance with pramlintide therapy
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
Pramlintide mimics natural amylin hormone by slowing gastric emptying, suppressing glucagon after meals, and promoting satiety. This combination reduces post-meal glucose spikes and supports weight management.
Research protocols typically start with 15 mcg for type 1 diabetes or 60 mcg for type 2 diabetes, administered subcutaneously before meals. Doses are gradually increased based on tolerability.
Pramlintide alone rarely causes hypoglycemia, but significantly increases risk when combined with insulin. Insulin doses often require 50% reduction when initiating pramlintide therapy.
Pramlintide effects begin within 20-30 minutes of injection, with peak gastric emptying effects occurring 1-2 hours post-dose. Full glycemic benefits develop over 2-4 weeks of consistent use.
Nausea affects 30-50% of users initially but typically decreases within 4-8 weeks. Other common effects include vomiting, decreased appetite, and injection site reactions.
No, pramlintide and insulin must be injected separately at different body sites. Mixing the medications can alter their absorption and effectiveness.
Opened pramlintide pens should be stored in the refrigerator at 2-8°C and used within 28 days. Never freeze the medication or leave it in hot conditions.
Yes, clinical studies show 2-4 kg weight loss over 6 months through enhanced satiety and reduced caloric intake. Weight benefits are maintained with continued use.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.